Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

ASTELLAS FARMA LDA

NIF 502540249
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €17,406,140 31 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €17,406,140 31 contracts
A2 · Late Publication €7,543,011,444 1,541 contracts
Contract published to BASE more than 10 days after the signing date
LOW €7,543,011,444 1,541 contracts
A5 · Threshold Splitting €8,645,097 38 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €8,645,097 38 contracts
A6 · Low Competition €2,996,519 28 contracts
Only one bidder participated in a competitive procedure
MEDIUM €2,996,519 28 contracts
A9 · Abnormal Price Reduction €9,136,952,664 653 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €9,136,952,664 653 contracts
C3 · Missing Mandatory Fields €8,086,995 41 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €8,086,995 41 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

166
€428,470,831
249
€417,372,943
55
€414,367,780
80
€404,546,691
22
€381,327,956
104
€381,137,980
26
€374,580,602
62
€373,018,895
19
€359,595,982
236
€350,867,378
63
€349,966,981
23
€335,053,171
18
€331,656,775
26
€327,454,836
12
€320,462,812
124
€272,332,829
154
€271,349,399
19
€269,977,703
28
€268,927,100
12
€267,768,845
Page 1 of 3 · 53 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 28 contracts

251X000053/13559 - VÁRIOS MEDICAMENTOS
PT · 11249214 · Contratação excluída II
A6 · Low Competition
€99,900 2025-02-25
C/BASE CPA 2023_491
PT · 11178104 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€43,832 2024-12-23
2024010854 – Aquisição de medicamentos
PT · 11102517 · Ajuste Direto Regime G...
A6 · Low Competition
€9,600 2024-12-20
IMUNOMODULADORES - TACROLÍMUS
PT · 11084015 · Ao abrigo de acordo-qu...
A6 · Low Competition
€17,529 2024-12-13
Aquisição do medicamento - enfortumab
PT · 11166677 · Ajuste Direto Regime G...
C3 · Missing Mandatory Fields A6 · Low Competition
€194,400 2024-11-25
2024009657 – Aquisição de medicamentos
PT · 11045657 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€9,600 2024-11-04
BEAD20240434 - AQUISIÇÃO DE ANTIHORMONAS ANTI-ANDROGENIOS - ENZALUTAMIDA - 3 MESES
PT · 10987932 · Ao abrigo de acordo-qu...
A6 · Low Competition
€140,572 2024-10-24
2024007767 – Aquisição de medicamentos
PT · 11005059 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€14,400 2024-10-23
IMUNOMODULADORES - TACROLÍMUS
PT · 10982109 · Ao abrigo de acordo-qu...
A6 · Low Competition
€15,789 2024-10-21
GILTERITINIB 40MG COM REVESTIDO
PT · 11231231 · Ao abrigo de acordo-qu...
C3 · Missing Mandatory Fields A6 · Low Competition
€373,488 2024-10-01
EX/2706/2024 - ELRATANAB 40MG/ML INJ 1.9MG
PT · 10903383 · Contratação excluída II
A6 · Low Competition
€97,200 2024-09-02
ENFORTUMAB VEDOTINA 20 MG PÓ CONC SOL INJ FR IV
PT · 10897007 · Ajuste Direto Regime G...
A6 · Low Competition
€30,000 2024-08-28
ANTIHORMONAS ANTI-ANDROGENIOS
PT · 10872332 · Ao abrigo de acordo-qu...
A6 · Low Competition
€140,572 2024-08-14
EX/2497/2024 – ENFORTUMAB VEDOTINA 30MG INJ
PT · 10884778 · Contratação excluída II
A2 · Late Publication A6 · Low Competition
€21,600 2024-08-02
2024006014 – Aquisição de medicamentos
PT · 10840801 · Ajuste Direto Regime G...
A6 · Low Competition
€12,000 2024-07-29
Aquisição de TACROLIMUS CAPS 0,5 MG, ao Lab. Astellas, para a ULSASI, para o ano 2024
PT · 10855420 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€1,128 2024-07-25
IMUNOMODULADORES - TACROLÍMUS
PT · 10831596 · Ao abrigo de acordo-qu...
A6 · Low Competition
€40,263 2024-07-15
ENZALUTAMIDA
PT · 10690644 · Ao abrigo de acordo-qu...
A6 · Low Competition
€68,908 2024-04-29
Aquisição de Tacrolímus 0,5mg cáps, Tacrolímus 1mg cáps e Tacrolímus 5mg cáps
PT · 11079597 · Ajuste Direto Regime G...
A2 · Late Publication A9 · Abnormal Price Reduction +1
€422,615 2024-03-15
2024001134 – Aquisição de medicamentos
PT · 10687354 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€165,379 2024-03-12
TACROLIMUS CAPSULAS
PT · 10981525 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€100,810 2024-02-29
Fornecimento de Enzalutamida ao Hospital de Santo Espírito da Ilha Terceira, EPER
PT · 10592045 · Ajuste Direto Regime G...
A6 · Low Competition
€275,632 2024-02-28
2024000810 – Aquisição de medicamentos
PT · 10569076 · Ajuste Direto Regime G...
A6 · Low Competition
€16,800 2024-02-19
MEDICAMENTOS EXCLUSIVOS - ASTELLAS FARMA
PT · 10981128 · Ajuste Direto Regime G...
A2 · Late Publication A6 · Low Competition
€126,000 2024-02-16
BEAD20240151 - AQUISIÇÃO DE IMUNOMODULADORES - TACROLÍMUS - 1º SEMESTRE
PT · 10564827 · Ao abrigo de acordo-qu...
A6 · Low Competition
€80,094 2024-02-16
241G000134-CITOSTATICOS E IMUNODEP.
PT · 10562530 · Ajuste Direto Regime G...
A5 · Threshold Splitting A6 · Low Competition
€148,407 2024-02-15
AQUISIÇÃO DE MEDICAMENTOS DE FORNECIMENTO EXCLUSIVO DO LABORATÓRIO ASTELLAS FARMA
PT · 10543950 · Ajuste Direto Regime G...
A6 · Low Competition
€66,000 2024-02-01
Aquisição de Medicamentos Exclusivos Astellas Farma para o ano de 2024
PT · 10493528 · Ajuste Direto Regime G...
A6 · Low Competition
€264,000 2024-01-19
Overview
Total Value Won
€9,273,228,876
Contracts Won
2,183
Score 72430 · CRITICAL RISK
NIF
502540249
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • C.L. [P-c41c]
    Gerente
    since 2023-11-21
  • J.M. [P-507f]
    Gerente
    since 2024-06-28
  • R.I. [P-b4a3]
    Gerente
    since 2026-03-26
  • R.M. [P-6a6b]
    Gerente
    since 2016-09-27
  • R.M. [P-6a6b]
    Gerente
    since 2024-06-28
  • A.P. [P-d113]
    Sócio
    since 2015-04-10
  • A.P. [P-7a72]
    Sócio
    since 2015-04-10
  • A.G. [P-3e39]
    Gerente
    2011-06-17 → 2016-03-24
  • D.B. [P-b4bb]
    Gerente
    2016-04-06 → 2018-09-26
  • E.T. [P-f3f8]
    Gerente
    2016-02-22 → 2018-09-17
  • E.T. [P-f3f8]
    Gerente
    2021-01-15 → 2021-09-20
  • F.J. [P-4794]
    Gerente
    2016-04-06 → 2026-03-26
  • G.K. [P-c72f]
    Gerente
    2011-06-17 → 2016-02-22
  • H.Z. [P-e82d]
    Gerente
    2021-09-22 → 2023-10-30
  • J.H. [P-32ac]
    Gerente
    2016-02-22 → 2016-04-06
  • N.J. [P-1516]
    Gerente
    2011-06-17 → 2016-02-22
  • P.A. [P-dc72]
    Gerente
    until 2011-06-01
  • R.J. [P-8e74]
    Gerente
    2011-06-17 → 2016-09-05
  • Y.I. [P-0359]
    Gerente
    until 2015-04-07
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned